![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Markey Looks for Answers on FDA’s Opioid Approval Process
Markey Looks for Answers on FDA’s Opioid Approval Process
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/PillsinMouth.gif?t=1474528434&width=430)
Citing a national opioid crisis and the frequency of deaths associated with OxyContin overdoses, a lawmaker is asking FDA Commissioner Robert Califf about how the agency administers Risk Evaluation and Mitigation Strategies for prescription opioids.
Sen. Edward Markey (D-Mass.) is calling for the FDA to require REMS for immediate-release opioids in addition to those already required for extended-release and long-acting opioids.
The senator also slammed the agency for approving Purdue Pharma’s OxyContin despite an advisory committee finding that its product-specific REMS were not sufficient.
Upcoming Events
-
21Oct